PFLUGERVILLE, Texas -- Demand for skincare products continues even amid skin cancer warnings. Now, companies are turning out new products in search of the Federal Drug Administration's approval.

One Central Texas clinical research facility has expanded to allow even more, first-hand product testing. That allows Austin area patients to benefit from cutting-edge treatments.

Tina Harmon is a patient of Ted Lain, M.D., a dermatologist at Pflugerville Dermatology. Recently, Lain determined Harmon had more than 15 precancerous lesions on her face, causing her great concern.

"Getting older, I wanted to get rid of them before they became cancer," Harmon said.

Lain suggested she take part in a clinical trial for a new cream seeking FDA approval that is designed to get rid of the lesions.

"We desperately need new treatments for different skin problems, including precancerous skin cancers and other very common diseases such as eczema, psoriasis or acne," Lain said. "What we have now is old."

Lain said the need for new treatments is due to some current products possibly having safety concerns. Harmon agreed to take part in the research.

"I wanted to be a part of the cutting-edge type of medications that are out there," she said. Luckily, she didn't have to travel far.

Adjacent to Pflugerville Dermatology is the Austin Institute for Clinical Research.

Lain has operated the clinical testing facility for three years, but he recently expanded it by 1,200 square feet to allow for more testing for cutting-edge technology and products.

"It allows me to see [the products] firsthand and to offer them early to the patients," he said. "When these products are approved, I'll have all the experience that other physicians just won't have yet, because I'll have treated 10 to 20, even 30, patients with the medication already."

Harmon is thrilled with her clinical trial experience.

"I have a clearer complexion, and it cleared up all of the pre-skin cancer," she said.

Participating in the trial, Harmon said, will also help future patients.

"If it's going to further the advancement of pre-skin cancer for people, [then] that's pretty exciting."

Go here for more information on clinical research.